JP2020520995A5 - - Google Patents

Download PDF

Info

Publication number
JP2020520995A5
JP2020520995A5 JP2020514156A JP2020514156A JP2020520995A5 JP 2020520995 A5 JP2020520995 A5 JP 2020520995A5 JP 2020514156 A JP2020514156 A JP 2020514156A JP 2020514156 A JP2020514156 A JP 2020514156A JP 2020520995 A5 JP2020520995 A5 JP 2020520995A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
cycloalkyl
hydroxyalkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020514156A
Other languages
English (en)
Japanese (ja)
Other versions
JP7212956B2 (ja
JP2020520995A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/033547 external-priority patent/WO2018213810A1/en
Publication of JP2020520995A publication Critical patent/JP2020520995A/ja
Publication of JP2020520995A5 publication Critical patent/JP2020520995A5/ja
Application granted granted Critical
Publication of JP7212956B2 publication Critical patent/JP7212956B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020514156A 2017-05-19 2018-05-18 皮膚障害の処置用のピロロピリジン-アニリン化合物 Active JP7212956B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762508997P 2017-05-19 2017-05-19
US62/508,997 2017-05-19
US201862663202P 2018-04-26 2018-04-26
US62/663,202 2018-04-26
PCT/US2018/033547 WO2018213810A1 (en) 2017-05-19 2018-05-18 Pyrrolopyridine-aniline compounds for treatment of dermal disorders

Publications (3)

Publication Number Publication Date
JP2020520995A JP2020520995A (ja) 2020-07-16
JP2020520995A5 true JP2020520995A5 (cg-RX-API-DMAC7.html) 2021-07-26
JP7212956B2 JP7212956B2 (ja) 2023-01-26

Family

ID=62620966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020514156A Active JP7212956B2 (ja) 2017-05-19 2018-05-18 皮膚障害の処置用のピロロピリジン-アニリン化合物

Country Status (16)

Country Link
US (4) US11161845B2 (cg-RX-API-DMAC7.html)
EP (1) EP3624796B1 (cg-RX-API-DMAC7.html)
JP (1) JP7212956B2 (cg-RX-API-DMAC7.html)
KR (1) KR102642411B1 (cg-RX-API-DMAC7.html)
CN (1) CN111065393B (cg-RX-API-DMAC7.html)
AU (1) AU2018270295B2 (cg-RX-API-DMAC7.html)
CA (1) CA3063536A1 (cg-RX-API-DMAC7.html)
DK (1) DK3624796T3 (cg-RX-API-DMAC7.html)
ES (1) ES3030506T3 (cg-RX-API-DMAC7.html)
FI (1) FI3624796T3 (cg-RX-API-DMAC7.html)
IL (1) IL270752B (cg-RX-API-DMAC7.html)
MA (1) MA49141A (cg-RX-API-DMAC7.html)
MX (2) MX389965B (cg-RX-API-DMAC7.html)
PL (1) PL3624796T3 (cg-RX-API-DMAC7.html)
PT (1) PT3624796T (cg-RX-API-DMAC7.html)
WO (1) WO2018213810A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2913213T3 (es) 2017-05-19 2022-06-01 Nflection Therapeutics Inc Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
JP7212956B2 (ja) * 2017-05-19 2023-01-26 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用のピロロピリジン-アニリン化合物
CN113660931B (zh) * 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物
WO2020106305A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
EP3883552B1 (en) 2018-11-20 2025-04-09 NFlection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
CN113473986B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤疾病萘啶酮苯胺化合物
CN113645964B (zh) * 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于胎记治疗的芳基苯胺和杂芳基苯胺化合物
JP2023547040A (ja) * 2020-09-24 2023-11-09 エヌフレクション セラピューティクス インコーポレイテッド ピロロピリジン-アニリン化合物による、認知機能不全の処置方法
AU2022210443A1 (en) * 2021-01-21 2023-09-07 Nflection Therapeutics, Inc. Processes for preparing pyrrolopyridine-aniline compounds
CN117157065A (zh) * 2021-01-21 2023-12-01 恩福莱克逊治疗有限公司 吡咯并吡啶-苯胺化合物的晶型
KR20240125577A (ko) 2021-11-23 2024-08-19 엔플렉션 테라퓨틱스, 인코포레이티드 피롤로피리딘-아닐린 화합물의 제형
AU2022398467A1 (en) * 2021-11-23 2024-06-27 Nflection Therapeutics, Inc. Formulations of pyrrolopyridine-aniline compounds
MX2024011403A (es) 2022-03-17 2024-09-23 Springworks Therapeutics Inc Tratamiento con mirdametinib.

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7674907B2 (en) 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
WO2006083979A2 (en) 2005-02-02 2006-08-10 Nexgenix Pharmaceuticals, L.L.C. Local treatment of neurofibromas
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
GB0601962D0 (en) * 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
CA2660546A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
WO2008024724A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
EP2113500A1 (en) 2006-10-31 2009-11-04 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
CA2672327A1 (en) * 2006-11-30 2008-06-05 Genentech, Inc. Aza-indolyl compounds and methods of use
US20080312307A1 (en) 2007-05-25 2008-12-18 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
CA2708176A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
GB0801081D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0801080D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
US8450344B2 (en) * 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US9422262B2 (en) 2010-09-24 2016-08-23 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US9357781B2 (en) 2013-05-03 2016-06-07 Inscent, Inc. Honeybee repellents and uses thereof
CN105384754B (zh) 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
JP7212956B2 (ja) 2017-05-19 2023-01-26 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用のピロロピリジン-アニリン化合物

Similar Documents

Publication Publication Date Title
JP2020520994A5 (cg-RX-API-DMAC7.html)
KR101651448B1 (ko) 체지방을 국소적으로 증가시키는 방법 및 조성물
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
CO2018005854A2 (es) Inhibidores de la proteína quinasa, método de preparación y uso médico de los mismos
RU2012101947A (ru) Способы лечения и профилактики усталости
EA035649B1 (ru) Применение агента, активирующего рецептор гамк, для получения седативного и анестезирующего лекарственного средства
JP6453441B2 (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ2a阻害剤
CN103619330A (zh) 用于治疗糖尿病的选择性雄激素受体调节剂
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
EP3391887A1 (en) Wound treatment agent
JP2014515407A5 (cg-RX-API-DMAC7.html)
JP2022511730A5 (cg-RX-API-DMAC7.html)
JP2022510587A5 (cg-RX-API-DMAC7.html)
EP2144887A1 (en) Dosages and methods for the treatment of cancer
KR20200052934A (ko) 경피 제제
KR20160005356A (ko) 방사선완화 약제학적 제형
WO2008124823A1 (en) Method of treating melanoma
JP2018522941A (ja) セバコイルジナルブフィンエステルの徐放のための医薬製剤
RU2018130097A (ru) Лечение экземы кистей
RU2017134553A (ru) Хорошо растворимые в воде соли фенилалкиламина - быстродействующего блокатора кальциевых каналов, и их применение
US20200030305A1 (en) Local anesthetic-containing acidic emulsion composition
AU2015321365A1 (en) A combination of kynurenine and antigen presenting cells (APC) as therapeutics and methods for their use in immune modulation
RU2015111137A (ru) Пиридиноновые соединения для применения в фотодинамической терапии
KR20220002965A (ko) 리포산 프로드러그
AU2017272198A1 (en) Sesame oil based injection formulations